Oldest pages
Jump to navigation
Jump to search
Showing below up to 500 results in range #201 to #700.
View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)
- Air-kerma, incident (17:32, 12 September 2019)
- Air-kerma, product (17:33, 12 September 2019)
- Alimentary tract transfer factor (17:34, 12 September 2019)
- Alpha decay (17:35, 12 September 2019)
- Alveolar-interstitial region (17:35, 12 September 2019)
- Angiogenesis (17:35, 12 September 2019)
- Annihilation photons (17:36, 12 September 2019)
- Annual dose (17:36, 12 September 2019)
- Area monitoring (17:37, 12 September 2019)
- Auger transition (17:37, 12 September 2019)
- Authorization (17:38, 12 September 2019)
- Authorized limit (17:38, 12 September 2019)
- Autoimmune disease (17:39, 12 September 2019)
- Autonomy (17:39, 12 September 2019)
- Averted dose (17:40, 12 September 2019)
- Wisdom (17:43, 12 September 2019)
- Waste disposal (17:43, 12 September 2019)
- Background dose (rate) (18:55, 12 September 2019)
- Basal cell (18:56, 12 September 2019)
- Benthic (18:57, 12 September 2019)
- Beta-minus decay (18:57, 12 September 2019)
- Beta-plus decay (18:58, 12 September 2019)
- Biomedical research volunteer (18:58, 12 September 2019)
- Bioturbation (18:59, 12 September 2019)
- Bone marrow (18:59, 12 September 2019)
- Bradycardia (18:59, 12 September 2019)
- Branching fraction (18:59, 12 September 2019)
- Bronchial region (19:00, 12 September 2019)
- Bystander effect (19:00, 12 September 2019)
- Qualified expert (19:03, 12 September 2019)
- Occupational exposure (19:07, 12 September 2019)
- Orphan source (19:07, 12 September 2019)
- Oversight (19:07, 12 September 2019)
- Cardiac arrhythmias (19:15, 12 September 2019)
- Cardiac valve diseases (19:16, 12 September 2019)
- Cardiomyopathy (19:16, 12 September 2019)
- Cardioverter-defibrillator (19:16, 12 September 2019)
- Chronic exposure (19:17, 12 September 2019)
- Class SR-0 gases (19:17, 12 September 2019)
- Class SR-1 gases (19:17, 12 September 2019)
- Class SR-2 gases (19:18, 12 September 2019)
- Clearance level (19:19, 12 September 2019)
- Clonogenic cells (19:19, 12 September 2019)
- Clonogenic survival (19:19, 12 September 2019)
- Co-expertise (19:19, 12 September 2019)
- Colony (19:20, 12 September 2019)
- Committed effective dose (19:20, 12 September 2019)
- Committed equivalent dose (19:20, 12 September 2019)
- Complex tissues (19:21, 12 September 2019)
- Computed tomography dose index (19:21, 12 September 2019)
- Connective tissue (19:21, 12 September 2019)
- Consequential late effects (19:21, 12 September 2019)
- Constancy test (19:21, 12 September 2019)
- Contamination (19:22, 12 September 2019)
- Coronary heart disease (19:23, 12 September 2019)
- Cost-benefit analysis (19:24, 12 September 2019)
- Coster-Kronig transition (19:25, 12 September 2019)
- Curie (19:25, 12 September 2019)
- Cytokines (19:26, 12 September 2019)
- Decay constant (19:28, 12 September 2019)
- Decommissioning (19:28, 12 September 2019)
- Decontamination (19:29, 12 September 2019)
- Decontamination factor (19:29, 12 September 2019)
- Deontological Ethics (19:30, 12 September 2019)
- Diastasis (19:30, 12 September 2019)
- Dichotomous (19:31, 12 September 2019)
- Differentiation (19:31, 12 September 2019)
- In vivo radiobioassay (19:32, 12 September 2019)
- Disposal (19:33, 12 September 2019)
- DNA damage signalling (19:33, 12 September 2019)
- Dose constraint (19:35, 12 September 2019)
- Dose criteria (19:35, 12 September 2019)
- Dose limit (19:36, 12 September 2019)
- Dose per unit intake coefficient (19:37, 12 September 2019)
- Dose rate (19:38, 12 September 2019)
- Dose rate effectiveness factor (19:38, 12 September 2019)
- Dose-rate effect (19:39, 12 September 2019)
- Dose-threshold (19:40, 12 September 2019)
- Early normal tissue responses (19:43, 12 September 2019)
- Edema (19:44, 12 September 2019)
- Effect Dose 50 (19:45, 12 September 2019)
- Effective charge number (19:46, 12 September 2019)
- Effective dose equivalent (19:47, 12 September 2019)
- Effective half-life (19:49, 12 September 2019)
- Electron-capture decay (19:49, 12 September 2019)
- Electrophysiology (19:51, 12 September 2019)
- Emergency (19:52, 12 September 2019)
- Emergency exposure situation (19:52, 12 September 2019)
- Emergency plan (19:53, 12 September 2019)
- Emergency preparedness (19:53, 12 September 2019)
- Emergency procedures (19:53, 12 September 2019)
- Endogeneous excretion (19:54, 12 September 2019)
- Environmental exposure (19:55, 12 September 2019)
- Environmental radiation protection (19:55, 12 September 2019)
- Epithelium (19:56, 12 September 2019)
- Erythropoietin (19:57, 12 September 2019)
- Ethics (19:58, 12 September 2019)
- Exempt waste (19:59, 12 September 2019)
- Exemption level (19:59, 12 September 2019)
- Existing exposure situation (20:00, 12 September 2019)
- Exponential survival curve (20:01, 12 September 2019)
- Exposure, external or internal (20:01, 12 September 2019)
- Exposure situation (20:02, 12 September 2019)
- Habitual mouth breather (12:42, 13 September 2019)
- Habitual nose breather (12:42, 13 September 2019)
- Half-life, physical (12:43, 13 September 2019)
- Hazard (12:43, 13 September 2019)
- Health Surveillance (12:43, 13 September 2019)
- Heliosphere (12:44, 13 September 2019)
- Hierarchical tissues (12:44, 13 September 2019)
- High level waste (12:45, 13 September 2019)
- Hormones (12:45, 13 September 2019)
- Hyperbaric oxygen (12:46, 13 September 2019)
- Hypertrophic cardiomyopathy (12:48, 13 September 2019)
- Hypoplasia (12:48, 13 September 2019)
- Immune system (12:49, 13 September 2019)
- Incident (12:50, 13 September 2019)
- Inclusiveness (12:50, 13 September 2019)
- Individual decontamination (12:50, 13 September 2019)
- Individual monitoring (12:51, 13 September 2019)
- Individual-related (12:51, 13 September 2019)
- Inhalability (12:53, 13 September 2019)
- Inner bremsstrahlung (12:53, 13 September 2019)
- Institutional control (12:54, 13 September 2019)
- Intermediate level waste (12:54, 13 September 2019)
- Internal conversion electron (12:56, 13 September 2019)
- Interphase death (12:56, 13 September 2019)
- Intervention Level (12:56, 13 September 2019)
- Interventional procedure (12:57, 13 September 2019)
- Iso-effect plots (12:58, 13 September 2019)
- Isomers (12:58, 13 September 2019)
- Isotropic geometry (12:58, 13 September 2019)
- Itinerant (radiation) worker (12:59, 13 September 2019)
- Latent time/period or latency interval (13:01, 13 September 2019)
- Limitation of dose (13:01, 13 September 2019)
- Lineal energy (13:02, 13 September 2019)
- Linear-non-threshold model (13:03, 13 September 2019)
- Low level waste (13:08, 13 September 2019)
- Lymphatic system (13:08, 13 September 2019)
- Macrophage colony stimulating factor (13:08, 13 September 2019)
- Magnetosphere (13:09, 13 September 2019)
- Member of the public (13:10, 13 September 2019)
- Mendelian diseases (13:10, 13 September 2019)
- Mitigation (13:10, 13 September 2019)
- Multistage tumorigenesis (13:11, 13 September 2019)
- Myocardial perfusion (13:12, 13 September 2019)
- Myocardial stress test (13:13, 13 September 2019)
- Naturally occurring radioactive material (13:14, 13 September 2019)
- Necrosis (13:14, 13 September 2019)
- Neurological syndrome (13:14, 13 September 2019)
- Neurovascular syndrome (13:15, 13 September 2019)
- Non-sphericity parameter (13:16, 13 September 2019)
- Nuclear track detectors (13:17, 13 September 2019)
- Particle radiance (13:28, 13 September 2019)
- Peak skin dose (13:28, 13 September 2019)
- Pelagic (13:29, 13 September 2019)
- Percutaneous coronary intervention (13:29, 13 September 2019)
- Pericarditis (13:29, 13 September 2019)
- Pharynx (13:30, 13 September 2019)
- Planned exposure situation (13:30, 13 September 2019)
- Platelet-derived growth factor (13:30, 13 September 2019)
- Practical radiological protection culture (13:32, 13 September 2019)
- Prevailing circumstances (13:32, 13 September 2019)
- Principle of application of dose limits (13:32, 13 September 2019)
- Principle of justification (13:33, 13 September 2019)
- Principle of optimisation (13:33, 13 September 2019)
- Procedural values (13:34, 13 September 2019)
- Progenitor cell (13:35, 13 September 2019)
- Projected dose (13:36, 13 September 2019)
- Protection strategy (13:37, 13 September 2019)
- Protective action (13:37, 13 September 2019)
- Protective action guide (13:38, 13 September 2019)
- Public exposure (13:39, 13 September 2019)
- Radiation modifier (13:41, 13 September 2019)
- Radiation safety officer (13:42, 13 September 2019)
- Radiation worker (13:44, 13 September 2019)
- Radioactive dispersion device (13:44, 13 September 2019)
- Radioactive source (13:45, 13 September 2019)
- Radioactive substance (13:46, 13 September 2019)
- Radioactivity (13:46, 13 September 2019)
- Radiofrequency ablation (13:46, 13 September 2019)
- Radiographer (13:48, 13 September 2019)
- Radiological protection principles (13:49, 13 September 2019)
- Radionuclides of natural origin (13:49, 13 September 2019)
- Radioresponsiveness (13:49, 13 September 2019)
- Radiosensitiser (13:50, 13 September 2019)
- Radiosensitivity, cellular (13:50, 13 September 2019)
- Reasonableness (13:50, 13 September 2019)
- Recovery (13:51, 13 September 2019)
- Recovery responder (13:51, 13 September 2019)
- Reference bioassay function (13:51, 13 September 2019)
- Reference biokinetic model (13:52, 13 September 2019)
- Reference level (13:52, 13 September 2019)
- Rehabilitation of living conditions (13:52, 13 September 2019)
- Relocation (13:53, 13 September 2019)
- Remedial action (13:53, 13 September 2019)
- Remediation (13:53, 13 September 2019)
- Repopulation (13:54, 13 September 2019)
- Representative organism (non-human biota) (13:54, 13 September 2019)
- Representative person (13:54, 13 September 2019)
- Reproductive integrity (13:55, 13 September 2019)
- Residual dose (13:55, 13 September 2019)
- Respiratory protection (13:55, 13 September 2019)
- Retrievability (13:56, 13 September 2019)
- Reversibility (13:56, 13 September 2019)
- Right to know (13:57, 13 September 2019)
- Rigidity (13:58, 13 September 2019)
- Routine monitoring (13:58, 13 September 2019)
- Safety case (13:59, 13 September 2019)
- Safety culture (13:59, 13 September 2019)
- Scintigraphy (13:59, 13 September 2019)
- Self-help protection (14:00, 13 September 2019)
- Slow repair (14:01, 13 September 2019)
- Solar cosmic radiation (14:01, 13 September 2019)
- Solar cycle (14:01, 13 September 2019)
- Solar particle event (14:01, 13 September 2019)
- Source term (14:02, 13 September 2019)
- Source-related (14:02, 13 September 2019)
- South Atlantic anomaly (14:03, 13 September 2019)
- Special (non-routine) monitoring (14:03, 13 September 2019)
- Spontaneous fission (14:03, 13 September 2019)
- Stakeholder (14:04, 13 September 2019)
- Stenosis (14:04, 13 September 2019)
- Storage (14:04, 13 September 2019)
- Subcutaneous tissue (14:05, 13 September 2019)
- Substantial radiation dose level (14:05, 13 September 2019)
- Systemic model (14:06, 13 September 2019)
- Tachycardia (14:10, 13 September 2019)
- Target region (14:10, 13 September 2019)
- Target tissue (14:10, 13 September 2019)
- Telangiectasia (14:11, 13 September 2019)
- Threshold dose for tissue reactions (14:11, 13 September 2019)
- Thyroid blocking (14:11, 13 September 2019)
- Time factor (14:11, 13 September 2019)
- Tissue equivalent material (14:12, 13 September 2019)
- Tolerability (14:12, 13 September 2019)
- Track structure (14:13, 13 September 2019)
- Transfer compartment (14:14, 13 September 2019)
- Transfer rate (14:14, 13 September 2019)
- Transforming growth factor (14:15, 13 September 2019)
- Transparency (14:15, 13 September 2019)
- Trapped particles (14:16, 13 September 2019)
- Types of materials (14:16, 13 September 2019)
- Application of ionising radiation in healthcare (old) (18:00, 9 October 2019)
- Information for patients, family members, carers and the public (old) (18:00, 9 October 2019)
- Information for healthcare providers (old) (18:00, 9 October 2019)
- Application of ionising radiation in healthcare (18:04, 9 October 2019)
- Information for patients, family members, carers and the public (18:11, 9 October 2019)
- Information for healthcare providers (18:21, 9 October 2019)
- ICRPædia Guides (18:33, 9 October 2019)
- List of ICRP Publications on Radiological Protection in Healthcare (13:57, 17 October 2019)
- Guide to Radiological Protection in Healthcare (13:59, 17 October 2019)
- The System of Radiological Protection (15:15, 23 October 2019)
- Quotes from Publications on the System of Radiological Protection (17:58, 23 October 2019)
- Guide to the System of Radiological Protection (15:40, 24 October 2019)
- General Information on Radon (12:41, 30 October 2019)
- System Of Radiation Protection Overview (15:02, 4 November 2019)
- System of radiation protection module 2 (15:11, 4 November 2019)
- Absorbed, Equivalent, and Effective Dose (21:54, 21 November 2019)
- Radon For Governments and Employers (18:19, 3 December 2019)
- Radon For Homeowners and Residents (18:19, 3 December 2019)
- Guide to Radon (07:37, 5 February 2020)
- Main Page (12:31, 18 November 2020)
- Additive risk projection model (20:28, 24 February 2021)
- Attributable risk (20:30, 24 February 2021)
- Dicentric chromosome (20:31, 24 February 2021)
- Effect modifier (20:32, 24 February 2021)
- Hereditary effect (20:33, 24 February 2021)
- Low dose (20:33, 24 February 2021)
- Low dose rate (20:35, 24 February 2021)
- Multiplicative risk projection model (20:36, 24 February 2021)
- Ring chromosome (20:38, 24 February 2021)
- Severe deterministic injury (20:38, 24 February 2021)
- Somatic effect (20:39, 24 February 2021)
- Transgenerational effect (20:40, 24 February 2021)
- Detriment-adjusted risk (20:42, 24 February 2021)
- Elemental dose (20:44, 24 February 2021)
- Multistage carcinogenesis model (20:50, 24 February 2021)
- Mutation component (20:51, 24 February 2021)
- Oncogene (20:52, 24 February 2021)
- Population risk (20:53, 24 February 2021)
- Potentially lethal damage repair (20:54, 24 February 2021)
- Radiation risk (20:55, 24 February 2021)
- Relative life lost (20:56, 24 February 2021)
- Risk model (20:57, 24 February 2021)
- Sublethal damage repair (20:58, 24 February 2021)
- Transfer of risk (20:59, 24 February 2021)
- Tumour suppressor gene (21:00, 24 February 2021)
- Acute radiation syndrome (21:40, 24 February 2021)
- Adaptive response (21:42, 24 February 2021)
- Α/β value (21:46, 24 February 2021)
- ΓH2AX foci (21:46, 24 February 2021)
- Informed consent (21:49, 24 February 2021)
- Supervised area (21:51, 24 February 2021)
- Access control (21:52, 24 February 2021)
- Acute exposure (21:54, 24 February 2021)
- Adventitious source (21:55, 24 February 2021)
- Authorised discharge (21:57, 24 February 2021)
- Backscatter factor (21:59, 24 February 2021)
- Best available techniques (22:00, 24 February 2021)
- Disposal facility (22:02, 24 February 2021)
- Dose modifying factor (22:03, 24 February 2021)
- Exposure pathway (22:05, 24 February 2021)
- Radiological controlled area (22:07, 24 February 2021)
- Life Span Study (22:10, 24 February 2021)
- Detriment (19:17, 25 February 2021)
- Baseline disease rates (19:29, 25 February 2021)
- Biomarker (19:31, 25 February 2021)
- Case–control study (19:33, 25 February 2021)
- Deterministic effect (19:38, 25 February 2021)
- Dose and dose-rate effectiveness factor (15:54, 26 February 2021)
- Dose-threshold hypothesis (15:56, 26 February 2021)
- Tissue reaction (16:00, 26 February 2021)
- Doubling dose (17:10, 26 February 2021)
- Epigenetic effects (17:13, 26 February 2021)
- Excess absolute risk (17:16, 26 February 2021)
- Excess relative risk (17:25, 26 February 2021)
- Homologous recombination (17:26, 26 February 2021)
- Incidence (17:28, 26 February 2021)
- Induced genomic instability (17:30, 26 February 2021)
- Late normal tissue responses (17:31, 26 February 2021)
- LD 50/30 (17:33, 26 February 2021)
- Lifetime risk estimates (17:42, 26 February 2021)
- Linear dose response (17:43, 26 February 2021)
- Linear-quadratic dose response model (17:48, 26 February 2021)
- Stochastic effect (17:58, 26 February 2021)
- Nominal risk coefficient (19:29, 26 February 2021)
- Non-homologous end joining (19:30, 26 February 2021)
- Non-targeted effects (19:31, 26 February 2021)
- Normal tissue complication probability (19:33, 26 February 2021)
- Pooled analysis (19:34, 26 February 2021)
- Quasi-threshold dose (19:35, 26 February 2021)
- Reactive oxygen species (19:36, 26 February 2021)
- Recovery (cellular or tissue) (19:38, 26 February 2021)
- Reference Animal and Plant (19:43, 26 February 2021)
- Relative biological effectiveness (20:22, 26 February 2021)
- Relative risk (20:25, 26 February 2021)
- Risk coefficient (20:30, 26 February 2021)
- Targeted effects (20:32, 26 February 2021)
- Translocation (20:33, 26 February 2021)
- Radiation source (21:04, 26 February 2021)
- Dose-response function (14:57, 28 March 2021)
- Tissue weighting factor (21:32, 28 March 2021)
- Absorption (22:15, 28 March 2021)
- Activation (22:16, 28 March 2021)
- Activity (22:19, 28 March 2021)
- ICRPædia Guide to the System of Radiological Protection (21:44, 3 May 2021)
- Active detection system (19:35, 11 August 2021)
- Additional dose (19:36, 11 August 2021)
- Allometry (19:37, 11 August 2021)
- Commissioning (19:42, 11 August 2021)
- Compartment (environmental) (19:44, 11 August 2021)
- Accreditation (19:45, 11 August 2021)
- Backscatter detection system (19:48, 11 August 2021)
- Clearance (19:50, 11 August 2021)
- Concentration ratio (19:52, 11 August 2021)
- Containment (19:56, 11 August 2021)
- Cosmic radiation (19:57, 11 August 2021)
- Derived reference level (20:00, 11 August 2021)
- Derived limit (20:00, 11 August 2021)
- Derived consideration reference level (20:02, 11 August 2021)
- Designated area (20:03, 11 August 2021)
- Evacuation (20:07, 11 August 2021)
- Exclusion (20:08, 11 August 2021)
- Exposed individuals (20:09, 11 August 2021)
- Frequent flyer (20:11, 11 August 2021)
- Ground-level enhancement (20:12, 11 August 2021)
- ICRU 4-element tissue (20:14, 11 August 2021)
- ICRU sphere (20:17, 11 August 2021)
- Intervention (20:18, 11 August 2021)
- Licensee (20:20, 11 August 2021)
- National radon survey (20:20, 11 August 2021)
- Nominal value (20:21, 11 August 2021)
- Occupancy factor (20:22, 11 August 2021)
- Operating management (20:23, 11 August 2021)
- Potential exposure (23:17, 11 August 2021)
- Collective dose (23:18, 11 August 2021)
- Optimisation of protection (23:22, 11 August 2021)
- Practice (23:25, 11 August 2021)
- Principles of protection (23:25, 11 August 2021)
- Radioactive waste (23:29, 11 August 2021)
- Radiological attack (23:30, 11 August 2021)
- Radon progeny (23:30, 11 August 2021)
- Radon-prone area (23:31, 11 August 2021)
- Redox (23:31, 11 August 2021)
- Reference value (23:34, 11 August 2021)
- Safety (23:36, 11 August 2021)
- Region (23:36, 11 August 2021)
- Sealed source (23:38, 11 August 2021)
- Solar flare (23:59, 11 August 2021)
- Sheltering (00:00, 12 August 2021)
- Security (00:01, 12 August 2021)
- Security screening (00:02, 12 August 2021)
- Protection quantities (14:51, 12 August 2021)
- Source-related assessment (14:53, 12 August 2021)
- Superposition principle (14:55, 12 August 2021)
- Surface contamination (14:56, 12 August 2021)
- Thoron progeny (14:57, 12 August 2021)
- Transmission detection system (14:59, 12 August 2021)
- Trophic level (15:00, 12 August 2021)
- Waste management (15:05, 12 August 2021)
- Worker (15:08, 12 August 2021)
- Working level (15:14, 12 August 2021)
- Working level month (15:17, 12 August 2021)
- Adenoma (15:24, 12 August 2021)
- Air kerma at the patient entrance reference point (15:27, 12 August 2021)
- Apoptosis (15:29, 12 August 2021)
- AML/eto (15:30, 12 August 2021)
- Automatic exposure control (15:33, 12 August 2021)
- Brachytherapy (15:34, 12 August 2021)
- Bragg peak (15:37, 12 August 2021)
- Spread-out Bragg peak (15:39, 12 August 2021)
- Breakpoint cluster region/abelson (15:41, 12 August 2021)
- Broad beam therapy irradiation technique (15:44, 12 August 2021)
- Carers and comforters (15:48, 12 August 2021)
- Clinical audit (15:50, 12 August 2021)
- Clonogenic surviving fraction (15:52, 12 August 2021)
- Cobblestone area forming cell assay (15:53, 12 August 2021)
- Collimation (15:54, 12 August 2021)
- Cone beam computed tomography (15:56, 12 August 2021)
- Dental and maxillofacial imaging (16:01, 12 August 2021)
- Exposure index (16:03, 12 August 2021)
- Detector quantum efficiency (16:04, 12 August 2021)
- Diagnostic reference level (16:09, 12 August 2021)
- Dose-length product (16:11, 12 August 2021)
- DRL process (16:14, 12 August 2021)
- DRL quantity (16:18, 12 August 2021)
- Exogenous excretion (16:19, 12 August 2021)
- Functional subunits (16:24, 12 August 2021)
- Hounsfield unit (16:43, 12 August 2021)
- Accelerated fractionation (16:45, 12 August 2021)
- Hyperfractionation (16:45, 12 August 2021)
- Intensity-modulated radiotherapy (16:46, 12 August 2021)
- Local DRL (16:49, 12 August 2021)
- National DRL (16:50, 12 August 2021)
- DRL value (16:51, 12 August 2021)
- Mean glandular dose (17:28, 12 August 2021)
- Multi-detector computed tomography (17:31, 12 August 2021)
- Multifactorial diseases (17:31, 12 August 2021)
- Multitarget equation (17:37, 12 August 2021)
- Noise (17:38, 12 August 2021)
- Notification value (17:41, 12 August 2021)
- Nuclear medicine (17:42, 12 August 2021)
- Molecular imaging (17:43, 12 August 2021)
- Organ at risk (17:44, 12 August 2021)
- Oxygen enhancement ratio (17:45, 12 August 2021)
- Pencil beam (17:46, 12 August 2021)
- Pilomatricoma (17:47, 12 August 2021)
- Potential recoverability correction factor (17:49, 12 August 2021)
- Quality control testing (17:51, 12 August 2021)
- Radiation-induced second cancer (17:52, 12 August 2021)
- Radiation-induced secondary malignancy (17:53, 12 August 2021)
- Ras (17:55, 12 August 2021)
- Rb (17:56, 12 August 2021)
- Referrer (17:57, 12 August 2021)
- Reference air kerma (17:59, 12 August 2021)
- Regional diagnostic reference levels (18:01, 12 August 2021)
- Registry (18:02, 12 August 2021)
- Relative survival (18:03, 12 August 2021)
- Secondary radiation (18:04, 12 August 2021)
- Shielding (18:05, 12 August 2021)
- Size-specific dose estimate (18:06, 12 August 2021)
- Slice (18:07, 12 August 2021)
- Standard-size adult (18:09, 12 August 2021)
- Stem cell (18:10, 12 August 2021)
- Teratocarcinoma (18:11, 12 August 2021)
- Time-resolved computed tomography (18:13, 12 August 2021)
- Tolerance dose (18:14, 12 August 2021)
- Digital breast tomosynthesis (18:15, 12 August 2021)
- Treatment preparation in radiotherapy (18:16, 12 August 2021)
- Typical value (18:18, 12 August 2021)
- Absorbed fraction (18:24, 12 August 2021)
- Source region (18:27, 12 August 2021)
- Activity median aerodynamic diameter (18:29, 12 August 2021)
- Ambient dose equivalent (18:30, 12 August 2021)
- Annual intake (18:31, 12 August 2021)
- Annual limit on intake (18:37, 12 August 2021)
- Derived air concentration (18:41, 12 August 2021)
- Biological half-life (18:43, 12 August 2021)
- Bronchiolar region (18:44, 12 August 2021)
- Charged-particle equilibrium (18:45, 12 August 2021)
- Collective effective dose (19:04, 12 August 2021)
- Compartment (19:06, 12 August 2021)
- Cross section (19:10, 12 August 2021)
- Cumulative dose (19:11, 12 August 2021)
- Deposition (19:13, 12 August 2021)
- Derived investigation level (19:14, 12 August 2021)
- Directional dose equivalent (19:16, 12 August 2021)
- Distribution coefficient (19:18, 12 August 2021)
- Dose (19:22, 12 August 2021)
- Absorbed dose (19:22, 12 August 2021)
- Equivalent dose (19:32, 12 August 2021)
- Dose commitment (19:40, 12 August 2021)
- Dose conversion convention (19:46, 12 August 2021)
- Dose conversion factor (19:47, 12 August 2021)
- Dose of record (E) (19:50, 12 August 2021)
- Dose of record Hp (10) (19:52, 12 August 2021)
- Dose per content function (18:26, 17 August 2021)
- DS86 (18:29, 17 August 2021)
- DS02 (18:29, 17 August 2021)
